August 21, 2024
ISOFOL MEDICAL AB (PUBL) PUBLISHES INTERIM REPORT
JANUARY-JUNE, 2024
July 16, 2024
NEW PRECLINICAL DATA SUPPORTING THE PREVIOUSLY COMMUNICATED CLINICAL DEVELOPMENT PLAN FOR ARFOLITIXORIN
About Isofol
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- November 04, 2024 - November 06, 2024
BIO-Europe, Stockholm, Sweden
Isofol will participate at BIO-Europe in Stockholm in November. We are available for individual meetings, follow the link above. - November 12, 2024 - November 12, 2024
Interim report July-September 2024 - November 20, 2024 - November 20, 2024
Investor meeting, autumn 2024
Isofol will arrange an investor meeting on November 20, 2024. The meeting will be held in Gothenburg and can also be followed via webcast. The Invitation and agenda will be published on the website, but save the date already now!
Media – Lates pressreleases
Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a…
Isofol terminates liquidity guarantee agreement
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement…
Isofol Medical AB (publ) publishes interim report, January–June 2024
GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
